Skip to Content
scroll

Opinion on Orthocell Ltd (OCC)

Our Q&As are emailed in our Saturday Morning Report, find the answer to this question below.

The Latest Q&A

Question asked

Opinion on Orthocell Ltd (OCC)

Thanks for your insightful opinions. It has assisted in developing my investing strategies. OCC has experienced significant growth in 2024 ahead of a raft of regulatory approvals including for the US. It appears to be consolidation ahead of actual revenue increases. Is this a case of buy the rumour sell the fact or is this pattern consistent with a pre-sales growth opportunity? Is this a familiar pattern? Thanks Peter

Answer

Hi Peter,

We have discussed OCC, a $315mn biotech a couple of times in 2025, delivering a favourable outlook on a space we rarely venture into. Slowly but surely OCC is moving in the right direction; in last few months they’ve received regulatory approval for Remplir in Hong Kong & Canada, and they’ve added eight new distributors for its nerve repair product.

  • We like OCC around $1.30 believing its consolidating recent stellar gains with the risk/reward now appealing after its recent pullback. That said, we are not big in this space, too many unknowns for us and binary outcomes.
chart
image description
Orthocell Ltd (OCC)
image description

Relevant suggested news and content from the site

Back to top